Sentences with phrase «pharmacological inhibitors of»

Fortunately, there are pharmacological inhibitors of the enzyme that produces these fatty acids.

«Importantly, we found that blocking the actions of the endocannabinoids with pharmacological inhibitors of cannabinoid receptors in the periphery completely normalized food intake and meal patterns in western diet - induced obese mice to levels found in control lean mice fed standard chow.»

I think it's really exciting that we showed that cancer cells deficient in these GATOR proteins are hypersensitive to this pharmacological inhibitor of mTOR, rapamycin.

Not exact matches

«Our research shows that targeting cannabinoid receptors in the periphery with pharmacological inhibitors that do not reach the brain holds promise as a safe therapeutic approach for the treatment of overeating and diet - induced obesity,» said Nicholas V. DiPatrizio, an assistant professor of biomedical sciences in the School of Medicine, who led the research project.

By using pharmacological small molecule inhibitors as well as neutrophils from genetically modified mouse strains the team could identify essential receptor and signaling pathways involved in the nicotine - mediated activation of neutrophils.

In their study, the researcher exploited this central position of EZH2 to combat the cancer: They used a pharmacological inhibitor to suppress the activity of EZH2.

These derivatives were identified through rational design and analyses of structural and pharmacological data from early reported CXCR4 inhibitors [96].

These are critical observations that will allow the field of autophagy to move beyond the utilization of lysosomal inhibitors for the pharmacological treatment of cancer by targeting autophagy.

It is now possible to determine the molecular structure of membrane proteins, previously difficult to characterize, offering better possibilities of developing pharmacological inhibitors for treating cancer and other diseases.

Microelectrode measurements and pharmacological inhibitor studies carried out on larval stages demonstrated that maintenance of alkaline gastric pH represents a substantial energy sink under acidified conditions that may contribute up to 30 % to the total energy budget.

The discovery of small molecule regulators (activators or inhibitors) of epigenetic modification enzymes provides researchers with pharmacological tools with which to investigate the biological consequences of chromatin modifications.

Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transporters

The DNA methyltransferase inhibitor 5 - azacytidine (AZA) is the most effective pharmacological option, but only ∼ 50 % of patients respond.

Although some people with hoarding problems may respond well to pharmacological strategies used in the treatment of OCD — such as SSRIs (selective serotonin reuptake inhibitors)-- the most effective treatment, says Dr Jeffreys, is behavioural therapy.

While antacids like Tums and other pharmacological solutions (H - 2 receptor blockers and proton pump inhibitors) can help manage acid reflux and gastroesophageal reflux disease, there are a handful of natural lifestyle modifications you can do that will keep symptoms at bay as well:

Some of these changes in gene expression can be reversed by pharmacological alterations of chromatin structure by the histone deacetylase inhibitor Trichostatin A (TSA) and the methyl donor L - methionine [19], [20].